{
"id":"mk19_bb_np_s22",
"subspecialtyId":"np",
"title":"Chronic Kidney Disease",
"jsonContent":{
"type":"section",
"id":"mk19_bb_np_s22",
"title":{
"__html":"Chronic Kidney Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"8b8b0b",
"children":[
"Chronic Kidney Disease"
]
},
"children":[
{
"type":"section",
"id":"mk19_bb_np_s22_1",
"title":{
"__html":"Screening"
},
"titleNode":{
"type":"section-title",
"hlId":"db7551",
"children":[
"Screening"
]
},
"children":[
{
"type":"p",
"hlId":"08c6dc",
"children":[
"Screening patients at risk for ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"chronic kidney disease",
"children":[
"CKD"
]
},
","
]
},
" including those with diabetes, hypertension, and a family history of kidney disease, is generally recommended."
]
}
]
},
{
"type":"section",
"id":"mk19_bb_np_s22_2",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"c9e800",
"children":[
"Diagnosis requires an ",
{
"type":"abbreviation",
"title":"estimated glomerular filtration rate",
"children":[
"eGFR"
]
},
" <60 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" confirmed at least 3 months after initial assessment, or persistent proteinuria or albuminuria regardless of eGFR. Kidney biopsy is used to determine the cause of CKD when a glomerular or tubulointerstitial disease is likely and when specific therapy is available to delay or prevent further kidney injury. Kidney biopsy is not routinely performed in the presence of shrunken kidneys (<9 cm), which generally indicate chronic irreversible disease."
]
},
{
"type":"p",
"hlId":"394440",
"children":[
"Differential diagnosis of CKD:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"bbc9ec",
"children":[
"Diabetic kidney disease: Look for early moderately increased albuminuria (spot albumin-creatinine ratio, 30-300 mg/g), followed by overt proteinuria, declining ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"glomerular filtration rate",
"children":[
"GFR"
]
},
","
]
},
" and a bland urine sediment. ",
{
"type":"alert",
"children":[
"The presence of retinopathy strongly suggests coexisting diabetic kidney disease."
]
}
]
},
" ",
{
"type":"list-item",
"hlId":"3c140c",
"children":[
"Glomerular disease: Look for glomerular hematuria, proteinuria, and hypertension, often with other systemic manifestations (",
{
"type":"abbreviation",
"title":"lupus nephritis",
"children":[
"LN"
]
},
" and postinfectious ",
{
"type":"abbreviation",
"title":"glomerulonephritis",
"children":[
"GN"
]
},
"). If nephrotic syndrome is present, look for focal segmental glomerulosclerosis, membranous nephropathy, and minimal change disease."
]
},
" ",
{
"type":"list-item",
"hlId":"582687",
"children":[
"Tubulointerstitial disease: Look for proteinuria, glycosuria, concentrating defect, sterile pyuria, and leukocyte casts, as well as papillary necrosis on ultrasound. Consider analgesic nephropathy (medication use, papillary necrosis), infection (",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"tuberculosis",
"children":[
"TB"
]
},
","
]
},
" legionnaires disease, leptospirosis), allergic drug reaction (eosinophilia, eosinophiluria), autoimmune disorder (",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"systemic lupus erythematosus",
"children":[
"SLE"
]
},
","
]
},
" sarcoidosis, Sjögren syndrome), and lead nephropathy (occupational exposure)."
]
},
" ",
{
"type":"list-item",
"hlId":"7d90b7",
"children":[
"Vascular disease: Look for hematuria, proteinuria, and associated systemic illness. Vasculitis often presents with ",
{
"type":"abbreviation",
"title":"rapidly progressive glomerulonephritis",
"children":[
"RPGN"
]
},
" and palpable purpura (leukocytoclastic vasculitis)."
]
},
" ",
{
"type":"list-item",
"hlId":"859e5b",
"children":[
"After transplantation: CKD in the kidney transplant recipient may be caused by chronic allograft nephropathy, drug toxicity (cyclosporine), polyomavirus BK infection, or recurrence of disease."
]
},
" ",
{
"type":"list-item",
"hlId":"a8555c",
"children":[
"Structural disease (polycystic kidney disease): Look for hypertension, hematuria, palpable kidneys (advanced disease), and family history of CKD."
]
},
" "
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"b5205c",
"children":[
"If the kidneys are markedly scarred and small (<9 cm), do not select aggressive diagnostic or therapeutic measures."
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_np_s22_3",
"title":{
"__html":"Complications"
},
"titleNode":{
"type":"section-title",
"hlId":"e24890",
"children":[
"Complications"
]
},
"children":[
{
"type":"p",
"hlId":"2ed537",
"children":[
"Many patients with CKD are asymptomatic. When CKD progresses to ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"end-stage kidney disease",
"children":[
"ESKD"
]
},
","
]
},
" uremic symptoms, such as fatigue, nausea, loss of appetite, insomnia, irritability, difficulty concentrating, confusion, or pruritus, may occur. Uremia may also induce pleuritis and pericarditis. Cardiovascular disease is the leading cause of death in patients with CKD. Chronic anemia, metabolic acidosis, and bone disease are also common complications."
]
},
{
"type":"p",
"hlId":"d6d202",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Renal osteodystrophy"
]
},
" refers to alteration of bone morphology in patients as a result of CKD."
]
},
{
"type":"p",
"hlId":"7fad63",
"children":[
"Acquired cystic kidney disease is common among patients with severe CKD and ESKD. These cysts are at increased risk for transformation into renal cell carcinoma. A high index of suspicion is warranted for patients with new gross hematuria, unexplained flank pain, or persistently elevated hemoglobin levels. For cysts that are highly suspicious for malignancy, partial nephrectomy is indicated for less severe stages of CKD. For patients with advanced CKD or ESKD, radical nephrectomy is preferred."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_bb_np_s22_inline_t1"
],
"forceOpen":true
}
]
},
{
"type":"section",
"id":"mk19_bb_np_s22_4",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"1120df",
"children":[
"Avoid exposure to kidney toxins (contrast agents, ",
{
"type":"abbreviation",
"title":"nonsteroidal anti-inflammatory drugs",
"children":[
"NSAIDs"
]
},
"). Avoid gadolinium-enhanced MRI because of the risk for nephrogenic systemic fibrosis (greatest risk in patients receiving dialysis). Begin restriction of sodium, potassium, and phosphorus. Avoid significant protein restriction. Drug and alkali therapy is based on specific findings."
]
},
{
"type":"p",
"hlId":"6fd94b",
"children":[
"In patients with CKD stages 3a to 5 not receiving dialysis:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"f6030f",
"children":[
"Lower elevated phosphorus levels toward the normal range but not into the normal range with diet modification and phosphate binders (sevelamer, lanthanum)."
]
},
" ",
{
"type":"list-item",
"hlId":"76e4f4",
"children":[
"Restrict or do not use calcium-based phosphate binders (calcium carbonate, calcium acetate)."
]
},
" ",
{
"type":"list-item",
"hlId":"bf7b1c",
"children":[
"Avoid hypercalcemia; mild and asymptomatic hypocalcemia can be tolerated."
]
},
" ",
{
"type":"list-item",
"hlId":"87572c",
"children":[
"Avoid routine use of calcitriol and vitamin D analogues to lower ",
{
"type":"abbreviation",
"title":"parathyroid hormone",
"children":[
"PTH"
]
},
" levels."
]
},
" "
]
},
{
"type":"p",
"hlId":"0b8c1b",
"children":[
"In patients receiving dialysis, calcimimetics, calcitriol, or vitamin D analogues, or their combination, should be used to lower PTH levels."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_bb_np_s22_inline_t2"
],
"forceOpen":true
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_bb_np_f08"
],
"forceOpen":true
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"594df6",
"children":[
"The anemia of CKD is a diagnosis of exclusion."
]
},
" ",
{
"type":"list-item",
"hlId":"23777b",
"children":[
"Do not use ",
{
"type":"abbreviation",
"title":"angiotensin-converting enzyme",
"children":[
"ACE"
]
},
" inhibitors in combination with ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"angiotensin receptor blocker",
"children":[
"ARB"
]
},
"s"
]
},
" or renin inhibitors to treat CKD patients with proteinuria."
]
},
" ",
{
"type":"list-item",
"hlId":"d68ebd",
"children":[
"Do not use magnesium-containing antacids in patients with ESKD."
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_np_s22_5",
"title":{
"__html":"Test Yourself"
},
"titleNode":{
"type":"section-title",
"hlId":"7866cc",
"children":[
"Test Yourself"
]
},
"children":[
{
"type":"p",
"hlId":"85f835",
"class":"test",
"children":[
"A 55-year-old woman with chronic lower back pain, polyuria, and nocturia is found to have CKD. Urinalysis shows no protein or erythrocytes, 5 to 10 leukocytes/hpf, and no casts. Urine culture shows no growth. Kidney ultrasound shows only papillary necrosis."
]
},
{
"type":"p",
"hlId":"cd0a3b",
"class":"test_answer",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Answer:"
]
},
" ",
"For diagnosis, choose tubulointerstitial disease secondary to analgesic abuse."
]
}
]
},
{
"type":"section",
"id":"mk19_bb_np_s22_6",
"title":{
"__html":"Kidney Replacement Therapy"
},
"titleNode":{
"type":"section-title",
"hlId":"661ab3",
"children":[
"Kidney Replacement Therapy"
]
},
"children":[
{
"type":"p",
"hlId":"ae732c",
"children":[
"Remember these points regarding kidney replacement therapy:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"e02fd5",
"children":[
"Clinical outcomes are equivalent for patients receiving peritoneal dialysis compared with hemodialysis."
]
},
" ",
{
"type":"list-item",
"hlId":"3149e3",
"children":[
"Peritoneal dialysis catheters are placed approximately 1 month before therapy is initiated."
]
},
" ",
{
"type":"list-item",
"hlId":"7f16cd",
"children":[
"Patients who opt for hemodialysis should be referred for arteriovenous fistula placement 2 months or more before their eGFR drops below 15 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" to allow sufficient time for arteriovenous fistula maturation."
]
},
" ",
{
"type":"list-item",
"hlId":"ef0b8e",
"children":[
"Kidney transplantation is associated with superior quality of life and improved survival and is less expensive than long-term dialysis."
]
},
" ",
{
"type":"list-item",
"hlId":"1b5408",
"children":[
"All patients with ESKD are considered candidates for kidney transplantation unless they have systemic malignancy, chronic infection, severe cardiovascular disease, or neuropsychiatric disorders."
]
},
" ",
{
"type":"list-item",
"hlId":"cbec03",
"children":[
"Transplantation is particularly beneficial in young patients."
]
},
" ",
{
"type":"list-item",
"hlId":"136633",
"children":[
"Suitable candidates for kidney transplantation should be referred for evaluation when their eGFR is 15 to 29 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"."
]
},
" "
]
},
{
"type":"p",
"hlId":"f1653a",
"children":[
"Patients with kidney transplants must receive immunosuppressive medications to prevent their immune system from rejecting the kidney allograft."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_bb_np_s22_inline_t3"
],
"forceOpen":true
},
{
"type":"p",
"hlId":"ee2537",
"children":[
"Immunosuppression increases the risk for infections and cancers."
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"c0a0ac",
"children":[
"The most common malignancy in kidney transplant recipients is cutaneous ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"squamous cell carcinoma",
"children":[
"SCC"
]
},
"."
]
}
]
},
" ",
{
"type":"list-item",
"hlId":"3fa9d0",
"children":[
"Kaposi sarcoma is much more common in kidney transplant recipients; reduce the immunosuppression and switch to sirolimus-based immunosuppression."
]
},
" ",
{
"type":"list-item",
"hlId":"e2828a",
"children":[
"Posttransplant lymphoproliferative disease is associated with ",
{
"type":"abbreviation",
"title":"Epstein-Barr virus",
"children":[
"EBV"
]
},
" infection; reduce immunosuppression and administration of rituximab in patients with CD20+ tumors."
]
},
" "
]
}
]
}
]
},
"tablesContent":{
"mk19_bb_np_s22_inline_t1":{
"id":"mk19_bb_np_s22_inline_t1",
"number":1,
"bookId":"np",
"title":{
"__html":"Study Table: Renal Osteodystrophy "
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"3d0e27",
"children":[
"Study Table: Renal Osteodystrophy "
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e2941",
"class":"col hd l",
"children":[
"Condition"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7a3d46",
"class":"col hd l",
"children":[
"Mechanism"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93932b",
"class":"col hd l",
"children":[
"Characteristics"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a45912",
"class":"cell txt l",
"children":[
"Osteitis fibrosa cystica"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"96ff54",
"class":"cell txt l",
"children":[
"Secondary hyperparathyroidism"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6e59af",
"class":"cell txt l",
"children":[
"Subperiosteal resorption of bone, most prominently at the phalanges"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d2bfd3",
"class":"cell txt l",
"children":[
"Adynamic bone disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7b1a81",
"class":"cell txt l",
"children":[
"Suppressed levels of PTH because of chronic illness or overly aggressive treatment with vitamin D analogues"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7bb1ac",
"class":"cell txt l",
"children":[
"Increased risk for fractures; made worse with bisphosphonate therapy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f8aa27",
"class":"cell txt l",
"children":[
"Osteomalacia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7001ea",
"class":"cell txt l",
"children":[
"Vitamin D deficiency"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cf6ea9",
"class":"cell txt l",
"children":[
"Bone pain, fractures"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_bb_np_s22_inline_t2":{
"id":"mk19_bb_np_s22_inline_t2",
"number":2,
"bookId":"np",
"title":{
"__html":"Study Table: Drug Therapy for CKD"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"6b9a4d",
"children":[
"Study Table: Drug Therapy for CKD"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd4b4a",
"class":"col hd l",
"children":[
"If you see this…"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0ffe9a",
"class":"col hd l",
"children":[
"Select…"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"01da3e",
"class":"cell txt l",
"children":[
"Hypertension"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aae5a6",
"class":"cell txt l",
"children":[
"BP target <120/80 mm Hg"
]
},
" ",
{
"type":"p",
"hlId":"404654",
"class":"cell txt l",
"children":[
"ACE inhibitor or ARB for patients with stage G1 CKD or higher with albuminuria"
]
},
" ",
{
"type":"p",
"hlId":"3dd1d6",
"class":"cell txt l",
"children":[
"Use a loop diuretic rather than a thiazide for GFR <30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9490da",
"class":"cell txt l",
"children":[
"Hyperlipidemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b29c88",
"class":"cell txt l",
"children":[
"Statin therapy in all patients ≥50 years with non–dialysis-dependent CKD and in adults aged 18-49 years with non–dialysis-dependent CKD and any one of the following: CAD, diabetes, previous ischemic stroke, or a >10% cardiovascular risk"
]
},
" ",
{
"type":"p",
"hlId":"fd70e4",
"class":"cell txt l",
"children":[
" ",
{
"type":"alert",
"children":[
"Do not treat patients receiving dialysis with statins (no benefit)"
]
},
" "
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fc45c6",
"class":"cell txt l",
"children":[
"Anemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a521df",
"class":"cell txt l",
"children":[
"Erythropoietin to maintain hemoglobin levels of 10-11 g/dL and iron to maintain iron stores (",
{
"type":"alert",
"children":[
"always check iron levels before starting erythropoietin "
]
},
"and maintain transferrin saturation levels >30% and serum ferritin levels >500 ng/mL)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"412a70",
"class":"cell txt l",
"children":[
"Metabolic acidosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b8acbb",
"class":"cell txt l",
"children":[
"Start alkali therapy when [HCO",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
"] is <22 mEq/L and maintain in normal range"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_bb_np_s22_inline_t3":{
"id":"mk19_bb_np_s22_inline_t3",
"number":3,
"bookId":"np",
"title":{
"__html":"Study Table: Common Adverse Effects of Immunosuppressants "
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"ba0311",
"children":[
"Study Table: Common Adverse Effects of Immunosuppressants "
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9bd813",
"class":"col hd l",
"children":[
"Class"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"353bd6",
"class":"col hd l",
"children":[
"Medication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"badfe0",
"class":"col hd l",
"children":[
"Common Side Effects"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1407fd",
"class":"cell txt l",
"children":[
"Calcineurin inhibitor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d5ad08",
"class":"cell txt l",
"children":[
"Cyclosporine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"815762",
"class":"cell txt l",
"children":[
"Hypertension, decreased GFR, dyslipidemia, hirsutism"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"273268",
"class":"cell txt l",
"children":[
"Tacrolimus"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"63f647",
"class":"cell txt l",
"children":[
"Diabetes, decreased GFR, hypertension"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7638b5",
"class":"cell txt l",
"children":[
"Antimetabolite"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1ed99c",
"class":"cell txt l",
"children":[
"Mycophenolate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"59220d",
"class":"cell txt l",
"children":[
"Leukopenia, anemia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ac0373",
"class":"cell txt l",
"children":[
"Azathioprine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c7d909",
"class":"cell txt l",
"children":[
"Leukopenia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d09ad7",
"class":"cell txt l",
"children":[
"mTOR inhibitor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2d3390",
"class":"cell txt l",
"children":[
"Sirolimus; everolimus"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c68f86",
"class":"cell txt l",
"children":[
"Proteinuria, dyslipidemia, diabetes, anemia, leukopenia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"51714b",
"class":"cell txt l",
"children":[
"Glucocorticoid receptor agonist"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0c03f2",
"class":"cell txt l",
"children":[
"Prednisone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"09fd2c",
"class":"cell txt l",
"children":[
"Osteopenia, hypertension, edema, diabetes"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
}
}
}